Business of Cannabis
Cannabis multistate operator Curaleaf is denying that it entered a supply agreement with Flora Growth after Flora Growth issued a press release on Oct. 30 suggesting just that.
“There is no agreement in place between Curaleaf and Flora Growth Corp.,” according to a Curaleaf statement provided to Cannabis Business Times through the company’s public relations team.
That statement came after Flora Growth indicated in Wednesday’s press release that it plans to target Germany’s cannabis market through a partnership with Curaleaf that involves importing Curaleaf’s medical cannabis strains and products. Flora Growth has an EU good manufacturing practice (GMP)-certified facility in Germany, according to the release.
“We are eager to partner with Curaleaf to bring their premium cannabis products to the German market.” Flora Growth CEO and Chairman Clifford Starke said in the release. “With the legal landscape evolving rapidly since the April 2024 legalization, there is a robust opportunity for cannabis to meet the needs of patients across Germany. At Flora, we remain committed to sourcing the best products, and Curaleaf’s proven expertise and quality align with our vision to serve this growing market through our EU-GMP facility.”
According to Curaleaf’s PR team at Mattio Communications, however, Flora Growth’s press release was distributed without Curaleaf’s knowledge and “is factually incorrect.”
When CBT reached out to Flora Growth for comment, Starke said, “We have had a supply agreement in place for years and its publicly available.”
